Search

CCX915

CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

T611

T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

Prednisolone phosphate

[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]

Zinc dibutyldithiocarbamate

Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

Imazaquin

2,5-di-tert-butylhydroquinone

Laquinimod

It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

Loracarbef

Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

Carbomer homopolymer type C

Carbomer homopolymer type C is a high molecular polyanionic substance tested for antiulcerogenic activity.

Potassium triiodide